Although no study has already been performed to investigate the impact of DDP4 inhibitors and/or GLP-1 agonists/analogs in lipodystrophy, it seems reasonable to suppose that they might be useful in these individuals, in a way that resembles its efficacy in type 2 diabetes and obesity. This evidence concerns the gene GCG and lipodystrophy.